Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 16/20 | 0.74 |
| ▸ | MAP2K2 | P36507 | 8/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748540 | 0.87 | MAP2K1 (0.72) | MAP2K1MAP2K2 | |
| SCHEMBL1488379 | 0.85 | MAP2K1 (0.71) | MAP2K1MAP2K2ALDH1A1 | |
| SCHEMBL29413559 | 0.85 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL30505247 | 0.85 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL5991001 | 0.85 | MAP2K1 (0.71) | MAP2K1MAP2K2MAPK1CLCN2 | |
| SCHEMBL188505 | 0.85 | MAP2K1 (1.00) | MAP2K1MAP2K2MAPK1 | |
| Hydrochloric Acid SCHEMBL30080174 | 0.84 | MAP2K1 (0.97) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL15698773 | 0.84 | MAP2K1 (0.59) | MAP2K1MAP2K2MAPK1MAPT | |
| SCHEMBL5991509 | 0.82 | MAP2K1 (0.66) | MAP2K1MAP2K2 | |
| SCHEMBL5992169 | 0.82 | MAP2K1 (0.66) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556112-B2 | Carboxylic acid ester prodrug inhibitors of MEK | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-01-31 | — | — | US | disclosed |
| US-20140135519-A1 | CARBOXYLIC ACID ESTER PRODRUG INHIBITORS OF MEK | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2014-05-15 | — | — | US | disclosed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| EP-1301472-B1 | OXYGENATED ESTERS OF 4-IODO PHENYLAMINO BENZHYDROXAMIC ACIDS | WARNER LAMBERT CO (US) | 2014-03-26 | — | — | EP | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-7411001-B2 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-6960614-B2 | Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | WARNER-LAMBERT COMPANY | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176820-A1 | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | CYP4X1, CYP2A7, CYP4B1 | MAP2K1 4341/4885MAP2K2 4268/4885MAPK1 4734/4885 |
| US-20140135519-A1 | CARBOXYLIC ACID ESTER PRODRUG INHIBITORS OF MEK | BRAF, MAPK1, KRAS | MAP2K1 37/4885MAP2K2 44/4885MAPK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.